Keysight Technologies (NYSE: KEYS) has released a new feature within its RF Circuit Simulation Professional software: an executable whiteboard. This tool aims to address the semiconductor talent gap by capturing engineers' RF design processes, including simulations and optimizations, and converting them into editable Python code. This allows for automated, repeatable workflows that can be shared, reused, and integrated into AI-driven design, preserving critical expertise and streamlining processes.

Healthcare sector analysts have expressed bullish sentiments towards Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP), and Cartesian Therapeutics (RNAC). Wells Fargo maintained a Buy rating on Eli Lilly with a $1280.00 target, while Mizuho Securities reiterated Buy ratings on Corbus Pharmaceuticals with a $44.00 target and Cartesian Therapeutics with a $29.75 target, highlighting significant upside potential for all three companies.

Cantor Fitzgerald maintained an Overweight rating and a $575 price target for Applied Materials (NASDAQ:AMAT), highlighting its strong position in the AI trade. The company, which has seen a 179% return over the past year, is expected by management to be in the early stages of AI's impact, with Agentic AI and increased CPU/DRAM demand anticipated to be 20% accretive to wafer fabrication equipment spending. Applied Materials is also focused on co-innovation, driving revenue growth, and returning free cash flow to shareholders.

This article compares Occidental Petroleum (OXY) and Exxon Mobil (XOM) after their recent earnings, highlighting their contrasting strategies. Occidental is focusing on becoming a pure-play Permian driller, having sold its chemicals division and reduced debt, while Exxon Mobil is pursuing growth through diversified global production, LNG exports, and consistent capital returns. The piece evaluates which company offers a better investment opportunity for 2026, considering their financial performance, market multiples, and future prospects in a $101.56 WTI crude oil environment.

Pomerantz LLP is investigating potential securities fraud claims against Entrada Therapeutics, Inc. (NASDAQ: TRDA) on behalf of its investors. This investigation follows a significant stock price drop after the company announced Phase 1/2 clinical study results for a Duchenne muscular dystrophy drug candidate, which showed a dystrophin increase deemed insufficient by the firm. Investors are encouraged to contact Pomerantz LLP for information regarding a potential class action.

UBS has reaffirmed its Buy rating and $70.00 price target for Bristol-Myers Squibb (NYSE:BMY), driven by the potential of its clinical trial data. A major catalyst is the upcoming Phase III atrial fibrillation data for milvexian, expected by year-end 2026, which could significantly boost revenue despite previous setbacks in the Factor XI inhibitor class. The stock is currently deemed undervalued by InvestingPro data, and positive trial results could lead to a substantial rally.

Michigan Orthopedic Center partnered with IntelePeer to develop a voice-based AI system that streamlines post-surgical patient assessments. This agentic AI tool gathers critical information on pain, wounds, and medication adherence, converting it into clinical summaries for EHRs. The initiative aims to reduce call volume, increase efficiency, and improve patient support without replacing staff, highlighting how specialized AI can benefit private practices.

Susan Wilkerson, SVP at Veeco Instruments (NASDAQ: VECO), sold 35,723 shares of the company's stock for a total of $2,203,751, according to a recent SEC filing. This insider transaction comes as Veeco Instruments faces revenue challenges and below-average EPS, despite a favorable debt-to-equity ratio and EV/EBITDA. While insider sells can have various motivations, the article emphasizes that investors should consider them alongside other financial metrics.

Best Buy Co. (NYSE:BBY) shares increased after reporting strong first-quarter adjusted EPS of $1.28 and sales of $8.94 billion, exceeding analyst expectations. The company saw comparable sales rise 2% year-over-year, driven by strength in gaming, computing, and mobile phones, and reaffirmed its FY2027 outlook for adjusted EPS and sales. Best Buy also declared a quarterly cash dividend of 96 cents per common share.

Two Harbors Investment Corp. has again postponed its shareholder vote on the proposed sale to CrossCountry Mortgage until June 11, indicating insufficient shareholder support for the current deal. This delay extends the public battle, with rival bidder UWM actively lobbying investors to reject the CrossCountry transaction. Two Harbors' board continues to advocate for the CrossCountry deal, emphasizing its certainty and advanced regulatory approvals, while criticizing UWM's proposal as potentially risky for shareholders.